Pour sensibiliser à la recherche et aux investissements dans les maladies rares. Les innovations dans les maladies rares valident des plateformes technologiques avec aussi des applications dans des maladies plus fréquentes. Merci à tous les acteurs. #RareDiseaseDay #Alnylam

Something to look forward to for #RNAi! 1st in 2018, 2nd in 2019, 3rd/4th in 2020... many more on the way!

A remarkable milestone in human genetics! Thank you Regeneron Genetics Center!

Thank you for your years of leadership John Maraganore 🇺🇸🇬🇷🇺🇦! The LS industry would not be where it is today if it weren’t for your persistence. Countless patients are in a better place because of you! MassBio Biotechnology Innovation Organization #thankyou #PatientDriven

I was honored to share my #IdeasinAction on how to help put an end to the #brainhealth pandemic at TEDxBoston #TEDxBoston. Together, we can help turn brain health awareness into action. Join Sage Therapeutics in shifting perspectives to see these disorders as diagnosable & treatable.

Thrilled to be joining ARCH as a Venture Partner as part of my plan to work with leading VCs! Looking forward to working w/ the team & the next generation of biotechs to advance promising science that can improve patients' lives. prnewswire.com/news-releases/…

In a Les Echos op-ed, I and other #BiotechSocialPact authors make the case for increased dialogue between French authorities and industry as France embarks on its #France2030 plan, aiming in part to make that country a leader in #biotech innovation again. bit.ly/3lNK2tr

Our outgoing CEO John Maraganore 🇺🇸🇬🇷🇺🇦 recently spoke with nature/Nature Reviews Drug Discovery about 20 years of #RNAi R&D, Alnylam's journey from #biotech startup in 2002 to where we are today, our #RNAitherapeutics pipeline and what's next for him personally. #siRNA go.nature.com/3yoI6wL

And so, my friends, it’s a wrap! Leaving Alnylam as CEO for the last time. The last 19+ years have been epic. Thanks to all my colleagues and supporters!

Honored to join n-Lorem Foundation as Advisory Council Chair and to work with Stanley Crooke, M.D., Ph.D.. Together we can help 100s of patients with #nanoraredisease!

Very excited to join Hemab Therapeutics as chair! Major opportunity to conquer rare bleeding disorders with innovation! Getting “band back together” w/ Benny Sorensen!

Honored to join Atlas Venture team and help build great biotech co’s again! Last time (Alnylam Pharmaceuticals) didn’t end up so bad! 😃😃

Very excited to join the Kymera Therapeutics board! Targeted protein degradation is a powerful platform for new medicines, and I’m thrilled to help realize the promise of the science for patients!

$BEAM and $KYMR have long become my favorite biotech companies. Both companies are innovative, ambitious, platform-based, with differentiated pipelines, and pioneers in their field. Now, John Maraganore 🇺🇸🇬🇷🇺🇦 has joined the board of directors of both companies. What a coincidence!

Such an amazing journey. Alnylam's 20th bday celebration today at MIT: new class of medicines, 5 launched, more to come. Helping patients in need. Way to go team Alnylam!

#AlnylamScienceSpotlight: Preclinical results demonstrating siRNA-mediated therapeutic silencing of target genes outside the liver, including in the CNS, eye, & lung were published this week in Nature Biotechnology. Delivery was achieved using Alnylam’s novel C16 conjugate technology.

Thank you Simone Fishburn 🎗️ for having me on the #BioCenturyShow to talk about Alnylam Pharmaceuticals and what’s next in the #RNAiRevolution! #RNAi

Happy #RNAday! #DYK that faulty mRNA (a type of #RNA) can produce proteins that cause disease? #RNAi therapeutics are designed to prevent this from happening by using #siRNA to target + degrade those mRNA before they produce disease-causing proteins. #RNAiTherapeutics #Alnylam20

is3na.org/post/celebrati…

Akshay reflecting on Alnylam resilience in fireside chat with Jason Rhodes at the Atlas Retreat.